<DOC>
	<DOCNO>NCT02856815</DOCNO>
	<brief_summary>To evaluate efficacy safety 'Immuncell-LC group ' 'non-treatment group ' patient undergo Transarterial Chemoembolization intermediate stage hepatocellular carcinoma</brief_summary>
	<brief_title>Clinical Trial Evaluate Efficacy Safety `` Immuncell-LC '' Patients Undergone TACE Intermediate Stage Hepatocellular Carcinoma</brief_title>
	<detailed_description>ILC-IIT-05 randomize , open-label , multi-center phase 2 clinical trial . To confirm clinical efficacy safety 'Immuncell-LC group ' 'non-treatment group ' , primary outcome , recurrence free survival ( RFS ) evaluate . For secondary outcome , overall survival ( OS ) , change Alpha Feto Protein ( AFP ) , correlation myeloid-derived suppressor cell change prognosis , adverse event , ECOG-PS hematological examination evaluate .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>Patients consent study provide signature self Patients 20 less 80 year old ChildPugh Class A ( score 56 ) B ( score 78 ) ECOG Performance Status ( ECOGPS ) score less 1 equal Patients diagnose BCLC stage B hepatocellular carcinoma pathological/radiological test ( Dynamic contrastenhanced CT Dynamic MRI ) tumor removal confirm TACE ( When patient diagnose recurrence hepatocellular carcinoma surgery local treatment , condition , patient could include ) Patients satisfy follow condition blood test kidney , liver function test Absolute neutrophil count &gt; 500/µL Hemoglobin ≥ 8.5 g/dL Platelet count &gt; 50,000/µL Blood Creatinine ≤ 1.5xupper normal limit Total bilirubin &lt; 3mg/dL Albumin ≥ 2.8g/dL Patients confirm residual tumor extrahepatic metastasis Patients lymph node metastasis portal vein , hepatic vein invasion Patients history treatment condition Liver transplantation From Informed consent form sign date , systemic chemotherapy 4 week ongoing adverse drug reaction anticancer drug 6 week External beam radiation , immunotherapy , molecular target therapy More 2 time systemic chemotherapy Biliary reconstruction endoscopic biliary treatment Patients history autoimmune disease ( Ex . Rheumatoid Arthritis , Systemic Lupus Erythematosus , Vasculitis , Multiple sclerosis , Adolescent InsulinDependent Diabetes Mellitus , etc . ) Patients history malignant tumor recent 5 year prior study except hepatocellular carcinoma Patients participate another clinical trial conduct treatment 4 week plan administration another clinical trial treatment since Informed consent form sign date Patients uncontrollable serious disease Pregnant woman nurse mother Patients intend get pregnant study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Immuncell-LC</keyword>
	<keyword>Transarterial Chemoembolization</keyword>
</DOC>